文献速递肿瘤 PET/CT放射性药物与辐射防护

68Ga-NT-20.3靶向神经降压素受体在胰腺导管腺癌患者中的安全性与耐受性:首次人体应用

Safety and tolerability of 68Ga-NT-20.3, a radiopharmaceutical for targeting neurotensin receptors, in patients with pancreatic ductal adenocarcinoma: the first in-human use.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-10-02

本研究首次在人体中评估68Ga-NT-20.3(靶向神经降压素受体的PET放射性药物)的安全性与耐受性。受试者按体重静脉注射2.5 MBq/kg的68Ga-DOTA-NT-20.3,并在注射后5-25、25-45、45-65、65-85分钟进行系列PET图像采集。结果表明该放射性药物安全且耐受性良好。

要点

  • 首次人体试验显示68Ga-NT-20.3安全且耐受性良好。
  • 给药剂量为2.5 MBq/kg体重,注射后多个时间点进行PET显像。
  • 生命体征在注射前、注射后即刻及3小时后监测。

核心结论

  • 68Ga-NT-20.3 PET放射性药物在胰腺导管腺癌患者中安全且耐受性良好。

研究设计与样本

  • 首次人体小样本试验,受试者静脉注射2.5 MBq/kg的68Ga-DOTA-NT-20.3,进行系列PET图像采集和生命体征监测。

主要发现

  • 注射后5-25、25-45、45-65、65-85分钟进行PET图像采集,并监测收缩压、舒张压、心率、呼吸频率、心电图和体温。

关键数值与推荐

  • 给药剂量为每公斤体重2.5 MBq的68Ga-DOTA-NT-20.3。
  • 生命体征在注射前、注射后即刻和3小时后检查。
  • 使用OLINDA/EXM版本2.1软件计算器官吸收剂量(自身剂量和交叉剂量)。

临床怎么用

  • 该放射性药物可用于靶向神经降压素受体的PET诊断,安全性支持进一步临床研究。

局限性

  • 试验样本量小,未报告具体受试者人数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Over the last decades, multiple peptide receptors were recognized as potential diagnostic and therapeutic targets in nuclear medicine. 68Ga-NT-20.3 radiopharmaceutical has been developed for diagnosis of neurotensin receptors. High neurotensin receptor expression has been observed in pancreatic ductal adenocarcinoma as well as various malignancies. Until now, 68Ga-labelled NT ligand was successfully applied in in vitro as well as in animal model. Our study is the first in-human study on safety and tolerability of 68Ga-NT-20.3. METHODS: Subjects were intravenously injected with 2.5 MBq of 68Ga-DOTA-NT-20.3 per kilogramme of body weight, and series of PET images were acquired at 5-25 min, 25-45 min, 45-65 min, and 65-85 min after 68Ga-NT-20.3 injection. Vital parameters are as follows: systolic and diastolic blood pressure (mmHg), heart rate (heart beat/min), respiratory rate (number of breaths/min), ECG, and body temperature (°C) were checked before, immediately after, and 3 h after 68Ga-NT-20.3 injection. The organ-absorbed doses were calculated for the self-dose and cross-dose from each organ region using the OLINDA/EXM version 2.1 software. RESULTS AND CONCLUSION: The results from this small trial demonstrate that PET radiopharmaceutical 68Ga-NT-20.3 is safe and well tolerated.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Hodolic M, Wu WY, Zhao Z, et al. Safety and tolerability of 68Ga-NT-20.3, a radiopharmaceutical for targeting neurotensin receptors, in patients with pancreatic ductal adenocarcinoma: the first in-human use. Eur J Nucl Med Mol Imaging. 2020. PMID: 33006657. doi:10.1007/s00259-020-05045-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。